JP6653120B2 - Ｉｋａｒｏｓ阻害に基づく抗炎症薬 - Google Patents

Info

Publication number

JP6653120B2

JP6653120B2 JP2015043590A JP2015043590A JP6653120B2 JP 6653120 B2 JP6653120 B2 JP 6653120B2 JP 2015043590 A JP2015043590 A JP 2015043590A JP 2015043590 A JP2015043590 A JP 2015043590A JP 6653120 B2 JP6653120 B2 JP 6653120B2

Authority

JP

Japan

Prior art keywords

ikaros

inflammatory

cells

gene

expression

Prior art date

2014-10-31

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Active

Links

• Espacenet
• Global Dossier
• Discuss

• 101150016712 IKZF1 gene Proteins 0.000 title claims description 430
• 102100037799 DNA-binding protein Ikaros Human genes 0.000 title claims description 351
• 229940124599 anti-inflammatory drug Drugs 0.000 title description 18
• 230000005764 inhibitory process Effects 0.000 title description 4
• 238000000034 method Methods 0.000 claims description 198
• 210000004027 cell Anatomy 0.000 claims description 187
• 230000014509 gene expression Effects 0.000 claims description 163
• 239000000126 substance Substances 0.000 claims description 138
• 206010061218 Inflammation Diseases 0.000 claims description 129
• 230000004054 inflammatory process Effects 0.000 claims description 128
• 210000002919 epithelial cell Anatomy 0.000 claims description 114
• 150000007523 nucleic acids Chemical class 0.000 claims description 114
• 102000039446 nucleic acids Human genes 0.000 claims description 103
• 108020004707 nucleic acids Proteins 0.000 claims description 103
• 108090000623 proteins and genes Proteins 0.000 claims description 98
• 241000282414 Homo sapiens Species 0.000 claims description 70
• 238000012360 testing method Methods 0.000 claims description 69
• 239000002260 anti-inflammatory agent Substances 0.000 claims description 66
• 102000004169 proteins and genes Human genes 0.000 claims description 62
• 241001465754 Metazoa Species 0.000 claims description 52
• 210000001519 tissue Anatomy 0.000 claims description 49
• 108020004459 Small interfering RNA Proteins 0.000 claims description 41
• 238000012216 screening Methods 0.000 claims description 36
• 230000001965 increasing effect Effects 0.000 claims description 34
• 208000027866 inflammatory disease Diseases 0.000 claims description 31
• 101000599038 Homo sapiens DNA-binding protein Ikaros Proteins 0.000 claims description 30
• 108010013958 Ikaros Transcription Factor Proteins 0.000 claims description 29
• 102000017182 Ikaros Transcription Factor Human genes 0.000 claims description 29
• 230000028709 inflammatory response Effects 0.000 claims description 27
• 230000027455 binding Effects 0.000 claims description 25
• 229940121363 anti-inflammatory agent Drugs 0.000 claims description 23
• 238000011282 treatment Methods 0.000 claims description 23
• 239000000203 mixture Substances 0.000 claims description 22
• 230000000638 stimulation Effects 0.000 claims description 20
• 239000003112 inhibitor Substances 0.000 claims description 19
• 210000004400 mucous membrane Anatomy 0.000 claims description 18
• 230000001105 regulatory effect Effects 0.000 claims description 16
• 230000002401 inhibitory effect Effects 0.000 claims description 15
• 230000003110 anti-inflammatory effect Effects 0.000 claims description 14
• 206010042033 Stevens-Johnson syndrome Diseases 0.000 claims description 11
• 231100000168 Stevens-Johnson syndrome Toxicity 0.000 claims description 11
• 238000005259 measurement Methods 0.000 claims description 11
• 230000002265 prevention Effects 0.000 claims description 9
• 230000002829 reductive effect Effects 0.000 claims description 9
• 230000008595 infiltration Effects 0.000 claims description 8
• 238000001764 infiltration Methods 0.000 claims description 8
• 230000002103 transcriptional effect Effects 0.000 claims description 8
• 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 6
• XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims description 6
• 229960002986 dinoprostone Drugs 0.000 claims description 4
• XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 claims description 4
• 102000003390 tumor necrosis factor Human genes 0.000 claims description 4
• 230000001747 exhibiting effect Effects 0.000 claims description 3
• 239000003860 topical agent Substances 0.000 claims description 2
• 108020004999 messenger RNA Proteins 0.000 description 84
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 64
• 108020004414 DNA Proteins 0.000 description 63
• 239000002773 nucleotide Substances 0.000 description 61
• 125000003729 nucleotide group Chemical group 0.000 description 60
• 230000000694 effects Effects 0.000 description 58
• 235000018102 proteins Nutrition 0.000 description 57
• 230000006870 function Effects 0.000 description 56
• 125000003275 alpha amino acid group Chemical group 0.000 description 51
• 239000003814 drug Substances 0.000 description 50
• 230000000295 complement effect Effects 0.000 description 43
• 235000001014 amino acid Nutrition 0.000 description 39
• 229940024606 amino acid Drugs 0.000 description 37
• 150000001413 amino acids Chemical class 0.000 description 36
• 241000699666 Mus <mouse, genus> Species 0.000 description 35
• 150000001875 compounds Chemical class 0.000 description 35
• 108091034117 Oligonucleotide Proteins 0.000 description 34
• 210000000981 epithelium Anatomy 0.000 description 34
• 239000013604 expression vector Substances 0.000 description 34
• 102000040430 polynucleotide Human genes 0.000 description 34
• 108091033319 polynucleotide Proteins 0.000 description 34
• 239000002157 polynucleotide Substances 0.000 description 34
• 230000000692 anti-sense effect Effects 0.000 description 32
• 230000002757 inflammatory effect Effects 0.000 description 32
• 229940079593 drug Drugs 0.000 description 31
• 108090000765 processed proteins & peptides Proteins 0.000 description 28
• 238000002347 injection Methods 0.000 description 27
• 239000007924 injection Substances 0.000 description 27
• 230000008685 targeting Effects 0.000 description 26
• 239000013598 vector Substances 0.000 description 26
• 210000003491 skin Anatomy 0.000 description 25
• 241000699670 Mus sp. Species 0.000 description 23
• 102000008230 Toll-like receptor 3 Human genes 0.000 description 23
• 108010060885 Toll-like receptor 3 Proteins 0.000 description 23
• 239000003795 chemical substances by application Substances 0.000 description 21
• 102000004196 processed proteins & peptides Human genes 0.000 description 21
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 20
• 108091027967 Small hairpin RNA Proteins 0.000 description 19
• -1 aromatic amino acids Chemical class 0.000 description 19
• 238000001514 detection method Methods 0.000 description 19
• 210000001339 epidermal cell Anatomy 0.000 description 19
• 239000000523 sample Substances 0.000 description 19
• 239000004055 small Interfering RNA Substances 0.000 description 19
• 241000283707 Capra Species 0.000 description 17
• 102000053642 Catalytic RNA Human genes 0.000 description 17
• 108090000994 Catalytic RNA Proteins 0.000 description 17
• 239000002609 medium Substances 0.000 description 17
• 229920001184 polypeptide Polymers 0.000 description 17
• 108091092562 ribozyme Proteins 0.000 description 17
• 102000005705 Keratin-5 Human genes 0.000 description 16
• 108010070553 Keratin-5 Proteins 0.000 description 16
• 239000002299 complementary DNA Substances 0.000 description 16
• 238000011830 transgenic mouse model Methods 0.000 description 16
• 230000014616 translation Effects 0.000 description 15
• 238000007796 conventional method Methods 0.000 description 14
• 210000002865 immune cell Anatomy 0.000 description 14
• 230000001939 inductive effect Effects 0.000 description 14
• 239000012488 sample solution Substances 0.000 description 14
• 102000004190 Enzymes Human genes 0.000 description 13
• 108090000790 Enzymes Proteins 0.000 description 13
• 108091028043 Nucleic acid sequence Proteins 0.000 description 13
• 239000000427 antigen Substances 0.000 description 13
• 230000001276 controlling effect Effects 0.000 description 13
• 238000004519 manufacturing process Methods 0.000 description 13
• 230000004048 modification Effects 0.000 description 13
• 238000012986 modification Methods 0.000 description 13
• 238000013519 translation Methods 0.000 description 13
• 102000040650 (ribonucleotides)n+m Human genes 0.000 description 12
• 108700019146 Transgenes Proteins 0.000 description 12
• 108091007433 antigens Proteins 0.000 description 12
• 102000036639 antigens Human genes 0.000 description 12
• 238000005516 engineering process Methods 0.000 description 12
• 238000002474 experimental method Methods 0.000 description 12
• 238000002372 labelling Methods 0.000 description 12
• 239000003550 marker Substances 0.000 description 12
• 239000008194 pharmaceutical composition Substances 0.000 description 12
• 102000004127 Cytokines Human genes 0.000 description 11
• 108090000695 Cytokines Proteins 0.000 description 11
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 11
• 206010028116 Mucosal inflammation Diseases 0.000 description 11
• 108010029485 Protein Isoforms Proteins 0.000 description 11
• 102000001708 Protein Isoforms Human genes 0.000 description 11
• 108700008625 Reporter Genes Proteins 0.000 description 11
• 238000007792 addition Methods 0.000 description 11
• 238000006243 chemical reaction Methods 0.000 description 11
• OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 11
• 201000010099 disease Diseases 0.000 description 11
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
• 239000012634 fragment Substances 0.000 description 11
• 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 11
• 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 11
• 238000006467 substitution reaction Methods 0.000 description 11
• 229940124597 therapeutic agent Drugs 0.000 description 11
• 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 description 10
• 208000026935 allergic disease Diseases 0.000 description 10
• 238000001727 in vivo Methods 0.000 description 10
• 230000006698 induction Effects 0.000 description 10
• 239000007788 liquid Substances 0.000 description 10
• 210000000056 organ Anatomy 0.000 description 10
• 239000013612 plasmid Substances 0.000 description 10
• 229920000642 polymer Polymers 0.000 description 10
• 102000053602 DNA Human genes 0.000 description 9
• 241000700159 Rattus Species 0.000 description 9
• PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 9
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 9
• 238000004458 analytical method Methods 0.000 description 9
• 230000037396 body weight Effects 0.000 description 9
• 210000000170 cell membrane Anatomy 0.000 description 9
• 239000003446 ligand Substances 0.000 description 9
• 102000005962 receptors Human genes 0.000 description 9
• 108020003175 receptors Proteins 0.000 description 9
• 230000009467 reduction Effects 0.000 description 9
• 239000007790 solid phase Substances 0.000 description 9
• 235000000346 sugar Nutrition 0.000 description 9
• 230000009261 transgenic effect Effects 0.000 description 9
• KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 8
• 241000282693 Cercopithecidae Species 0.000 description 8
• 201000004624 Dermatitis Diseases 0.000 description 8
• 241000124008 Mammalia Species 0.000 description 8
• 108091081021 Sense strand Proteins 0.000 description 8
• 238000004422 calculation algorithm Methods 0.000 description 8
• 210000002615 epidermis Anatomy 0.000 description 8
• 238000010195 expression analysis Methods 0.000 description 8
• 238000009396 hybridization Methods 0.000 description 8
• 238000003018 immunoassay Methods 0.000 description 8
• 229920001223 polyethylene glycol Polymers 0.000 description 8
• 239000002243 precursor Substances 0.000 description 8
• 108091008146 restriction endonucleases Proteins 0.000 description 8
• 150000003384 small molecules Chemical class 0.000 description 8
• 238000013518 transcription Methods 0.000 description 8
• 230000035897 transcription Effects 0.000 description 8
• 238000011144 upstream manufacturing Methods 0.000 description 8
• AUHDWARTFSKSAC-HEIFUQTGSA-N (2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-(6-oxo-1H-purin-9-yl)oxolane-2-carboxylic acid Chemical group [C@]1([C@H](O)[C@H](O)[C@@H](CO)O1)(N1C=NC=2C(O)=NC=NC12)C(=O)O AUHDWARTFSKSAC-HEIFUQTGSA-N 0.000 description 7
• 206010012438 Dermatitis atopic Diseases 0.000 description 7
• 239000002202 Polyethylene glycol Substances 0.000 description 7
• 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 7
• 230000004913 activation Effects 0.000 description 7
• HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 7
• 201000008937 atopic dermatitis Diseases 0.000 description 7
• 206010009887 colitis Diseases 0.000 description 7
• IERHLVCPSMICTF-XVFCMESISA-N cytidine 5'-monophosphate Chemical group O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 IERHLVCPSMICTF-XVFCMESISA-N 0.000 description 7
• 239000002552 dosage form Substances 0.000 description 7
• 230000009368 gene silencing by RNA Effects 0.000 description 7
• 238000010353 genetic engineering Methods 0.000 description 7
• 210000004962 mammalian cell Anatomy 0.000 description 7
• 239000000463 material Substances 0.000 description 7
• 238000002360 preparation method Methods 0.000 description 7
• 150000003180 prostaglandins Chemical class 0.000 description 7
• 239000000243 solution Substances 0.000 description 7
• WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
• 241000283690 Bos taurus Species 0.000 description 6
• 241000282472 Canis lupus familiaris Species 0.000 description 6
• 206010010744 Conjunctivitis allergic Diseases 0.000 description 6
• HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 6
• GRSZFWQUAKGDAV-UHFFFAOYSA-N Inosinic acid Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-UHFFFAOYSA-N 0.000 description 6
• 241000283973 Oryctolagus cuniculus Species 0.000 description 6
• 241001494479 Pecora Species 0.000 description 6
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 6
• ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical group O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 6
• 208000002205 allergic conjunctivitis Diseases 0.000 description 6
• 208000006673 asthma Diseases 0.000 description 6
• 208000024998 atopic conjunctivitis Diseases 0.000 description 6
• 230000015572 biosynthetic process Effects 0.000 description 6
• 210000004369 blood Anatomy 0.000 description 6
• 239000008280 blood Substances 0.000 description 6
• 239000000284 extract Substances 0.000 description 6
• 230000000984 immunochemical effect Effects 0.000 description 6
• 235000013902 inosinic acid Nutrition 0.000 description 6
• 239000004245 inosinic acid Substances 0.000 description 6
• 229940028843 inosinic acid Drugs 0.000 description 6
• 230000003993 interaction Effects 0.000 description 6
• 210000000440 neutrophil Anatomy 0.000 description 6
• 238000007911 parenteral administration Methods 0.000 description 6
• 239000000546 pharmaceutical excipient Substances 0.000 description 6
• 239000000829 suppository Substances 0.000 description 6
• 208000024891 symptom Diseases 0.000 description 6
• 239000003826 tablet Substances 0.000 description 6
• RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 6
• 108020004705 Codon Proteins 0.000 description 5
• 206010009900 Colitis ulcerative Diseases 0.000 description 5
• 208000011231 Crohn disease Diseases 0.000 description 5
• 241000701022 Cytomegalovirus Species 0.000 description 5
• 101150074155 DHFR gene Proteins 0.000 description 5
• 241000282326 Felis catus Species 0.000 description 5
• 101710163270 Nuclease Proteins 0.000 description 5
• 238000012300 Sequence Analysis Methods 0.000 description 5
• 201000006704 Ulcerative Colitis Diseases 0.000 description 5
• 241000700605 Viruses Species 0.000 description 5
• 239000002253 acid Substances 0.000 description 5
• 230000001154 acute effect Effects 0.000 description 5
• 210000004102 animal cell Anatomy 0.000 description 5
• 230000008901 benefit Effects 0.000 description 5
• 230000004071 biological effect Effects 0.000 description 5
• 239000000872 buffer Substances 0.000 description 5
• 230000015556 catabolic process Effects 0.000 description 5
• 238000012790 confirmation Methods 0.000 description 5
• 238000010276 construction Methods 0.000 description 5
• 238000012258 culturing Methods 0.000 description 5
• 229940104302 cytosine Drugs 0.000 description 5
• 238000006731 degradation reaction Methods 0.000 description 5
• 229920003045 dextran sodium sulfate Polymers 0.000 description 5
• 235000013305 food Nutrition 0.000 description 5
• 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 5
• 238000000338 in vitro Methods 0.000 description 5
• 238000010253 intravenous injection Methods 0.000 description 5
• 210000004698 lymphocyte Anatomy 0.000 description 5
• 239000012528 membrane Substances 0.000 description 5
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 5
• 239000002777 nucleoside Substances 0.000 description 5
• 239000000047 product Substances 0.000 description 5
• 230000000069 prophylactic effect Effects 0.000 description 5
• 238000000746 purification Methods 0.000 description 5
• 238000003757 reverse transcription PCR Methods 0.000 description 5
• 206010039073 rheumatoid arthritis Diseases 0.000 description 5
• 239000002904 solvent Substances 0.000 description 5
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
• NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 4
• 206010012442 Dermatitis contact Diseases 0.000 description 4
• 241000588724 Escherichia coli Species 0.000 description 4
• 241000238631 Hexapoda Species 0.000 description 4
• 241000282412 Homo Species 0.000 description 4
• 101001056473 Homo sapiens Keratin, type II cytoskeletal 5 Proteins 0.000 description 4
• 102000014150 Interferons Human genes 0.000 description 4
• 108010050904 Interferons Proteins 0.000 description 4
• 108060001084 Luciferase Proteins 0.000 description 4
• 108700011259 MicroRNAs Proteins 0.000 description 4
• 241000699660 Mus musculus Species 0.000 description 4
• 101100452381 Mus musculus Ikzf1 gene Proteins 0.000 description 4
• 238000010222 PCR analysis Methods 0.000 description 4
• ALLWOAVDORUJLA-UHFFFAOYSA-N Rebamipida Chemical compound C=1C(=O)NC2=CC=CC=C2C=1CC(C(=O)O)NC(=O)C1=CC=C(Cl)C=C1 ALLWOAVDORUJLA-UHFFFAOYSA-N 0.000 description 4
• 108091081024 Start codon Proteins 0.000 description 4
• 230000009471 action Effects 0.000 description 4
• 239000004480 active ingredient Substances 0.000 description 4
• 125000000539 amino acid group Chemical group 0.000 description 4
• 206010069664 atopic keratoconjunctivitis Diseases 0.000 description 4
• 230000004888 barrier function Effects 0.000 description 4
• SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 4
• 239000002775 capsule Substances 0.000 description 4
• 239000000969 carrier Substances 0.000 description 4
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 4
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
• 208000010247 contact dermatitis Diseases 0.000 description 4
• 238000011161 development Methods 0.000 description 4
• 230000018109 developmental process Effects 0.000 description 4
• 239000003085 diluting agent Substances 0.000 description 4
• 235000013601 eggs Nutrition 0.000 description 4
• 238000011156 evaluation Methods 0.000 description 4
• 238000012239 gene modification Methods 0.000 description 4
• 230000005017 genetic modification Effects 0.000 description 4
• 235000013617 genetically modified food Nutrition 0.000 description 4
• 102000055354 human IKZF1 Human genes 0.000 description 4
• 102000057575 human KRT5 Human genes 0.000 description 4
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
• 238000012744 immunostaining Methods 0.000 description 4
• 150000002632 lipids Chemical class 0.000 description 4
• 239000007791 liquid phase Substances 0.000 description 4
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
• 230000007246 mechanism Effects 0.000 description 4
• 230000010534 mechanism of action Effects 0.000 description 4
• YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 4
• 239000002679 microRNA Substances 0.000 description 4
• 238000010369 molecular cloning Methods 0.000 description 4
• 210000001616 monocyte Anatomy 0.000 description 4
• 229940094443 oxytocics prostaglandins Drugs 0.000 description 4
• 230000007170 pathology Effects 0.000 description 4
• 230000035699 permeability Effects 0.000 description 4
• 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 4
• 239000006187 pill Substances 0.000 description 4
• 230000001737 promoting effect Effects 0.000 description 4
• 238000011002 quantification Methods 0.000 description 4
• 238000003753 real-time PCR Methods 0.000 description 4
• 229950004535 rebamipide Drugs 0.000 description 4
• 238000011160 research Methods 0.000 description 4
• 150000003839 salts Chemical class 0.000 description 4
• 230000035945 sensitivity Effects 0.000 description 4
• 238000003786 synthesis reaction Methods 0.000 description 4
• 230000002194 synthesizing effect Effects 0.000 description 4
• 241000701161 unidentified adenovirus Species 0.000 description 4
• 230000003827 upregulation Effects 0.000 description 4
• 238000001262 western blot Methods 0.000 description 4
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
• 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 3
• 241000196324 Embryophyta Species 0.000 description 3
• 108700039887 Essential Genes Proteins 0.000 description 3
• 208000009386 Experimental Arthritis Diseases 0.000 description 3
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
• 108010043121 Green Fluorescent Proteins Proteins 0.000 description 3
• 102000004144 Green Fluorescent Proteins Human genes 0.000 description 3
• 206010020751 Hypersensitivity Diseases 0.000 description 3
• 206010021118 Hypotonia Diseases 0.000 description 3
• UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 3
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
• 239000005089 Luciferase Substances 0.000 description 3
• 238000000636 Northern blotting Methods 0.000 description 3
• 108700026244 Open Reading Frames Proteins 0.000 description 3
• 238000011529 RT qPCR Methods 0.000 description 3
• 241000714474 Rous sarcoma virus Species 0.000 description 3
• 241000251131 Sphyrna Species 0.000 description 3
• 241000282898 Sus scrofa Species 0.000 description 3
• 239000002671 adjuvant Substances 0.000 description 3
• 239000000556 agonist Substances 0.000 description 3
• 230000007815 allergy Effects 0.000 description 3
• 238000000137 annealing Methods 0.000 description 3
• 238000013459 approach Methods 0.000 description 3
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
• 102000005936 beta-Galactosidase Human genes 0.000 description 3
• 108010005774 beta-Galactosidase Proteins 0.000 description 3
• 230000008827 biological function Effects 0.000 description 3
• 239000012472 biological sample Substances 0.000 description 3
• 238000004113 cell culture Methods 0.000 description 3
• 238000005859 coupling reaction Methods 0.000 description 3
• 238000012136 culture method Methods 0.000 description 3
• 230000016396 cytokine production Effects 0.000 description 3
• 230000002950 deficient Effects 0.000 description 3
• 230000002255 enzymatic effect Effects 0.000 description 3
• 239000003889 eye drop Substances 0.000 description 3
• 210000000744 eyelid Anatomy 0.000 description 3
• 208000017561 flaccidity Diseases 0.000 description 3
• 125000000524 functional group Chemical group 0.000 description 3
• 239000005090 green fluorescent protein Substances 0.000 description 3
• 239000003018 immunosuppressive agent Substances 0.000 description 3
• 238000010874 in vitro model Methods 0.000 description 3
• 208000015181 infectious disease Diseases 0.000 description 3
• 210000004969 inflammatory cell Anatomy 0.000 description 3
• 210000002490 intestinal epithelial cell Anatomy 0.000 description 3
• 210000002510 keratinocyte Anatomy 0.000 description 3
• 238000011813 knockout mouse model Methods 0.000 description 3
• 210000004379 membrane Anatomy 0.000 description 3
• 229910052751 metal Inorganic materials 0.000 description 3
• 239000002184 metal Substances 0.000 description 3
• 150000002739 metals Chemical class 0.000 description 3
• 229960000485 methotrexate Drugs 0.000 description 3
• 238000004848 nephelometry Methods 0.000 description 3
• 150000003833 nucleoside derivatives Chemical class 0.000 description 3
• 125000003835 nucleoside group Chemical group 0.000 description 3
• 229910052760 oxygen Inorganic materials 0.000 description 3
• 239000001301 oxygen Substances 0.000 description 3
• 239000013600 plasmid vector Substances 0.000 description 3
• 238000000926 separation method Methods 0.000 description 3
• 150000003431 steroids Chemical class 0.000 description 3
• 238000007920 subcutaneous administration Methods 0.000 description 3
• 238000001356 surgical procedure Methods 0.000 description 3
• 238000011200 topical administration Methods 0.000 description 3
• 241001430294 unidentified retrovirus Species 0.000 description 3
• 229940035893 uracil Drugs 0.000 description 3
• 108020004491 Antisense DNA Proteins 0.000 description 2
• 102100037435 Antiviral innate immune response receptor RIG-I Human genes 0.000 description 2
• 101710127675 Antiviral innate immune response receptor RIG-I Proteins 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• 102000014914 Carrier Proteins Human genes 0.000 description 2
• 102000000503 Collagen Type II Human genes 0.000 description 2
• 108010041390 Collagen Type II Proteins 0.000 description 2
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
• 108020004635 Complementary DNA Proteins 0.000 description 2
• 206010010741 Conjunctivitis Diseases 0.000 description 2
• 241000699800 Cricetinae Species 0.000 description 2
• WCZDQPXNBJTKPI-UHFFFAOYSA-O Cyanidin 7-glucoside Chemical compound OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C(C=C(O)C(=[O+]2)C=3C=C(O)C(O)=CC=3)C2=C1 WCZDQPXNBJTKPI-UHFFFAOYSA-O 0.000 description 2
• 229930183912 Cytidylic acid Natural products 0.000 description 2
• IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 2
• 230000007018 DNA scission Effects 0.000 description 2
• CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 2
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
• BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 2
• 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• 108010060309 Glucuronidase Proteins 0.000 description 2
• 102000053187 Glucuronidase Human genes 0.000 description 2
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
• NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
• WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
• 101000953492 Homo sapiens Inositol hexakisphosphate and diphosphoinositol-pentakisphosphate kinase 1 Proteins 0.000 description 2
• 101001082073 Homo sapiens Interferon-induced helicase C domain-containing protein 1 Proteins 0.000 description 2
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
• 102000004157 Hydrolases Human genes 0.000 description 2
• 108090000604 Hydrolases Proteins 0.000 description 2
• 229930010555 Inosine Natural products 0.000 description 2
• 102100037739 Inositol hexakisphosphate and diphosphoinositol-pentakisphosphate kinase 1 Human genes 0.000 description 2
• 102100027353 Interferon-induced helicase C domain-containing protein 1 Human genes 0.000 description 2
• 102000004890 Interleukin-8 Human genes 0.000 description 2
• 108090001007 Interleukin-8 Proteins 0.000 description 2
• 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 2
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
• DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 2
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
• 241000713869 Moloney murine leukemia virus Species 0.000 description 2
• 101100442582 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) spe-1 gene Proteins 0.000 description 2
• 239000004677 Nylon Substances 0.000 description 2
• 108010038807 Oligopeptides Proteins 0.000 description 2
• 102000015636 Oligopeptides Human genes 0.000 description 2
• 229910019142 PO4 Inorganic materials 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
• 108010039918 Polylysine Proteins 0.000 description 2
• 238000011530 RNeasy Mini Kit Methods 0.000 description 2
• 241000283984 Rodentia Species 0.000 description 2
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
• 229920002472 Starch Polymers 0.000 description 2
• 229930006000 Sucrose Natural products 0.000 description 2
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
• 241000282887 Suidae Species 0.000 description 2
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
• 108091023045 Untranslated Region Proteins 0.000 description 2
• DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
• 235000010724 Wisteria floribunda Nutrition 0.000 description 2
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
• 238000010521 absorption reaction Methods 0.000 description 2
• 230000002378 acidificating effect Effects 0.000 description 2
• DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
• UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
• 238000005273 aeration Methods 0.000 description 2
• 230000000172 allergic effect Effects 0.000 description 2
• 239000003708 ampul Substances 0.000 description 2
• 238000010171 animal model Methods 0.000 description 2
• RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
• 239000003816 antisense DNA Substances 0.000 description 2
• 208000010668 atopic eczema Diseases 0.000 description 2
• 238000002869 basic local alignment search tool Methods 0.000 description 2
• 235000019445 benzyl alcohol Nutrition 0.000 description 2
• 229960002903 benzyl benzoate Drugs 0.000 description 2
• 108091008324 binding proteins Proteins 0.000 description 2
• 238000001574 biopsy Methods 0.000 description 2
• 229910052796 boron Inorganic materials 0.000 description 2
• 210000004556 brain Anatomy 0.000 description 2
• 210000004899 c-terminal region Anatomy 0.000 description 2
• 239000001506 calcium phosphate Substances 0.000 description 2
• 229910000389 calcium phosphate Inorganic materials 0.000 description 2
• 235000011010 calcium phosphates Nutrition 0.000 description 2
• 229910052799 carbon Inorganic materials 0.000 description 2
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
• 239000004359 castor oil Substances 0.000 description 2
• 235000019438 castor oil Nutrition 0.000 description 2
• 125000002091 cationic group Chemical group 0.000 description 2
• 238000005119 centrifugation Methods 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• 238000007385 chemical modification Methods 0.000 description 2
• 239000003153 chemical reaction reagent Substances 0.000 description 2
• 235000012000 cholesterol Nutrition 0.000 description 2
• 238000003776 cleavage reaction Methods 0.000 description 2
• 238000000975 co-precipitation Methods 0.000 description 2
• 230000002860 competitive effect Effects 0.000 description 2
• 239000002537 cosmetic Substances 0.000 description 2
• IERHLVCPSMICTF-UHFFFAOYSA-N cytidine monophosphate Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(COP(O)(O)=O)O1 IERHLVCPSMICTF-UHFFFAOYSA-N 0.000 description 2
• 210000000805 cytoplasm Anatomy 0.000 description 2
• 230000007423 decrease Effects 0.000 description 2
• 238000013461 design Methods 0.000 description 2
• XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
• 238000009826 distribution Methods 0.000 description 2
• 239000008298 dragée Substances 0.000 description 2
• 238000009509 drug development Methods 0.000 description 2
• 238000001962 electrophoresis Methods 0.000 description 2
• 238000004520 electroporation Methods 0.000 description 2
• 230000001804 emulsifying effect Effects 0.000 description 2
• 239000000839 emulsion Substances 0.000 description 2
• 108010048367 enhanced green fluorescent protein Proteins 0.000 description 2
• 210000003386 epithelial cell of thymus gland Anatomy 0.000 description 2
• 210000005081 epithelial layer Anatomy 0.000 description 2
• 230000029142 excretion Effects 0.000 description 2
• 239000013613 expression plasmid Substances 0.000 description 2
• 229940012356 eye drops Drugs 0.000 description 2
• 239000007941 film coated tablet Substances 0.000 description 2
• 238000001914 filtration Methods 0.000 description 2
• 229910052731 fluorine Inorganic materials 0.000 description 2
• 125000001153 fluoro group Chemical group F* 0.000 description 2
• 238000009472 formulation Methods 0.000 description 2
• 230000002496 gastric effect Effects 0.000 description 2
• 210000001035 gastrointestinal tract Anatomy 0.000 description 2
• 230000002068 genetic effect Effects 0.000 description 2
• 208000016759 gingival fibromatosis-progressive deafness syndrome Diseases 0.000 description 2
• 239000008103 glucose Substances 0.000 description 2
• 150000004676 glycans Polymers 0.000 description 2
• ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
• 239000008187 granular material Substances 0.000 description 2
• 235000013402 health food Nutrition 0.000 description 2
• 125000000623 heterocyclic group Chemical group 0.000 description 2
• 238000004128 high performance liquid chromatography Methods 0.000 description 2
• 210000004408 hybridoma Anatomy 0.000 description 2
• JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
• 125000001165 hydrophobic group Chemical group 0.000 description 2
• 230000036039 immunity Effects 0.000 description 2
• 229940124589 immunosuppressive drug Drugs 0.000 description 2
• 230000006872 improvement Effects 0.000 description 2
• 238000011534 incubation Methods 0.000 description 2
• 230000002718 inhibitory effect on inflammation Effects 0.000 description 2
• 229960003786 inosine Drugs 0.000 description 2
• 238000003780 insertion Methods 0.000 description 2
• 230000037431 insertion Effects 0.000 description 2
• 229940079322 interferon Drugs 0.000 description 2
• 229940047124 interferons Drugs 0.000 description 2
• 230000003834 intracellular effect Effects 0.000 description 2
• 238000010255 intramuscular injection Methods 0.000 description 2
• 239000007927 intramuscular injection Substances 0.000 description 2
• 239000000644 isotonic solution Substances 0.000 description 2
• 239000008101 lactose Substances 0.000 description 2
• 230000000670 limiting effect Effects 0.000 description 2
• 239000002502 liposome Substances 0.000 description 2
• 238000009630 liquid culture Methods 0.000 description 2
• 239000008297 liquid dosage form Substances 0.000 description 2
• 231100000053 low toxicity Toxicity 0.000 description 2
• HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 2
• 210000002540 macrophage Anatomy 0.000 description 2
• 235000019359 magnesium stearate Nutrition 0.000 description 2
• 230000001404 mediated effect Effects 0.000 description 2
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
• 244000005700 microbiome Species 0.000 description 2
• 238000000520 microinjection Methods 0.000 description 2
• 239000007758 minimum essential medium Substances 0.000 description 2
• 238000002156 mixing Methods 0.000 description 2
• 238000004264 monolayer culture Methods 0.000 description 2
• 210000005087 mononuclear cell Anatomy 0.000 description 2
• 238000010172 mouse model Methods 0.000 description 2
• 210000004877 mucosa Anatomy 0.000 description 2
• 239000007923 nasal drop Substances 0.000 description 2
• 239000002736 nonionic surfactant Substances 0.000 description 2
• 229920001778 nylon Polymers 0.000 description 2
• 238000002515 oligonucleotide synthesis Methods 0.000 description 2
• 239000008203 oral pharmaceutical composition Substances 0.000 description 2
• 239000012071 phase Substances 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
• 239000010452 phosphate Substances 0.000 description 2
• 239000002504 physiological saline solution Substances 0.000 description 2
• 229920000656 polylysine Polymers 0.000 description 2
• 102000054765 polymorphisms of proteins Human genes 0.000 description 2
• 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
• 229920001282 polysaccharide Polymers 0.000 description 2
• 239000005017 polysaccharide Substances 0.000 description 2
• 229940068968 polysorbate 80 Drugs 0.000 description 2
• 229920000053 polysorbate 80 Polymers 0.000 description 2
• 230000004481 post-translational protein modification Effects 0.000 description 2
• 239000000843 powder Substances 0.000 description 2
• 239000002244 precipitate Substances 0.000 description 2
• 210000000064 prostate epithelial cell Anatomy 0.000 description 2
• ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
• 150000003212 purines Chemical class 0.000 description 2
• 150000003230 pyrimidines Chemical class 0.000 description 2
• 230000005855 radiation Effects 0.000 description 2
• 238000003127 radioimmunoassay Methods 0.000 description 2
• 108010054624 red fluorescent protein Proteins 0.000 description 2
• 230000004044 response Effects 0.000 description 2
• 230000000717 retained effect Effects 0.000 description 2
• 230000002441 reversible effect Effects 0.000 description 2
• 239000003161 ribonuclease inhibitor Substances 0.000 description 2
• 239000002342 ribonucleoside Substances 0.000 description 2
• YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
• 230000007017 scission Effects 0.000 description 2
• 238000010517 secondary reaction Methods 0.000 description 2
• 239000008159 sesame oil Substances 0.000 description 2
• 235000011803 sesame oil Nutrition 0.000 description 2
• 238000002741 site-directed mutagenesis Methods 0.000 description 2
• 210000004927 skin cell Anatomy 0.000 description 2
• 239000007901 soft capsule Substances 0.000 description 2
• 239000007787 solid Substances 0.000 description 2
• 239000007909 solid dosage form Substances 0.000 description 2
• 239000003549 soybean oil Substances 0.000 description 2
• 235000012424 soybean oil Nutrition 0.000 description 2
• 239000008107 starch Substances 0.000 description 2
• 235000019698 starch Nutrition 0.000 description 2
• 239000007929 subcutaneous injection Substances 0.000 description 2
• 238000010254 subcutaneous injection Methods 0.000 description 2
• 239000000758 substrate Substances 0.000 description 2
• 239000005720 sucrose Substances 0.000 description 2
• 150000005846 sugar alcohols Polymers 0.000 description 2
• 239000007940 sugar coated tablet Substances 0.000 description 2
• 239000002511 suppository base Substances 0.000 description 2
• 230000001629 suppression Effects 0.000 description 2
• 239000000725 suspension Substances 0.000 description 2
• 235000020357 syrup Nutrition 0.000 description 2
• 239000006188 syrup Substances 0.000 description 2
• 238000007910 systemic administration Methods 0.000 description 2
• 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 2
• RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
• 238000001890 transfection Methods 0.000 description 2
• 238000012546 transfer Methods 0.000 description 2
• 230000001131 transforming effect Effects 0.000 description 2
• 230000014621 translational initiation Effects 0.000 description 2
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
• YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
• 210000003932 urinary bladder Anatomy 0.000 description 2
• 239000013603 viral vector Substances 0.000 description 2
• 108091005957 yellow fluorescent proteins Proteins 0.000 description 2
• 229910052725 zinc Inorganic materials 0.000 description 2
• 239000011701 zinc Substances 0.000 description 2
• DVWJFTGEISXVSH-CWVFEVJCSA-N (1R,3S,5S,7Z,11R,12S,13Z,15Z,17Z,19Z,21R,23S,24R,25S)-21-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-12-ethyl-1,3,5,25-tetrahydroxy-11-methyl-9-oxo-10,27-dioxabicyclo[21.3.1]heptacosa-7,13,15,17,19-pentaene-24-carboxylic acid Chemical compound CC[C@H]1\C=C/C=C\C=C/C=C\[C@@H](C[C@@H]2O[C@@](O)(C[C@H](O)[C@H]2C(O)=O)C[C@@H](O)C[C@@H](O)C\C=C/C(=O)O[C@@H]1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](N)[C@@H]1O DVWJFTGEISXVSH-CWVFEVJCSA-N 0.000 description 1
• KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
• BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
• GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 1
• JUDOLRSMWHVKGX-UHFFFAOYSA-N 1,1-dioxo-1$l^{6},2-benzodithiol-3-one Chemical compound C1=CC=C2C(=O)SS(=O)(=O)C2=C1 JUDOLRSMWHVKGX-UHFFFAOYSA-N 0.000 description 1
• VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical group C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 description 1
• NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
• ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
• 108020005345 3' Untranslated Regions Proteins 0.000 description 1
• VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
• 108020003589 5' Untranslated Regions Proteins 0.000 description 1
• UJBCLAXPPIDQEE-UHFFFAOYSA-N 5-prop-1-ynyl-1h-pyrimidine-2,4-dione Chemical class CC#CC1=CNC(=O)NC1=O UJBCLAXPPIDQEE-UHFFFAOYSA-N 0.000 description 1
• 102100023990 60S ribosomal protein L17 Human genes 0.000 description 1
• WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 description 1
• MROJXXOCABQVEF-UHFFFAOYSA-N Actarit Chemical compound CC(=O)NC1=CC=C(CC(O)=O)C=C1 MROJXXOCABQVEF-UHFFFAOYSA-N 0.000 description 1
• 229920000936 Agarose Polymers 0.000 description 1
• 241000589158 Agrobacterium Species 0.000 description 1
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
• 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
• 108091023037 Aptamer Proteins 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
• 229930003347 Atropine Natural products 0.000 description 1
• 208000023275 Autoimmune disease Diseases 0.000 description 1
• 108090001008 Avidin Proteins 0.000 description 1
• 244000063299 Bacillus subtilis Species 0.000 description 1
• 235000014469 Bacillus subtilis Nutrition 0.000 description 1
• 208000009137 Behcet syndrome Diseases 0.000 description 1
• BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
• ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
• 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
• 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
• KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
• 208000005024 Castleman disease Diseases 0.000 description 1
• 208000002177 Cataract Diseases 0.000 description 1
• 241000700198 Cavia Species 0.000 description 1
• 108010055166 Chemokine CCL5 Proteins 0.000 description 1
• 239000004380 Cholic acid Substances 0.000 description 1
• 208000035473 Communicable disease Diseases 0.000 description 1
• 241000699802 Cricetulus griseus Species 0.000 description 1
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
• 108010036949 Cyclosporine Proteins 0.000 description 1
• 230000006820 DNA synthesis Effects 0.000 description 1
• 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
• 101710096438 DNA-binding protein Proteins 0.000 description 1
• 241000702421 Dependoparvovirus Species 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• 101001048065 Drosophila melanogaster E3 ubiquitin-protein ligase HRD1 Proteins 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• 241000701959 Escherichia virus Lambda Species 0.000 description 1
• 108091062183 EsiRNA Proteins 0.000 description 1
• 108010008165 Etanercept Proteins 0.000 description 1
• 108060002716 Exonuclease Proteins 0.000 description 1
• 206010063006 Facial spasm Diseases 0.000 description 1
• 108010000916 Fimbriae Proteins Proteins 0.000 description 1
• 241000233866 Fungi Species 0.000 description 1
• 241000287828 Gallus gallus Species 0.000 description 1
• 229940122498 Gene expression inhibitor Drugs 0.000 description 1
• 208000010412 Glaucoma Diseases 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 239000007995 HEPES buffer Substances 0.000 description 1
• 208000004095 Hemifacial Spasm Diseases 0.000 description 1
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
• 101001066129 Homo sapiens Glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
• 102000003839 Human Proteins Human genes 0.000 description 1
• 108090000144 Human Proteins Proteins 0.000 description 1
• RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
• 208000008454 Hyperhidrosis Diseases 0.000 description 1
• 241000571697 Icarus Species 0.000 description 1
• 206010061598 Immunodeficiency Diseases 0.000 description 1
• 208000029462 Immunodeficiency disease Diseases 0.000 description 1
• 101710090028 Inositol-3-phosphate synthase 1 Proteins 0.000 description 1
• 102100026720 Interferon beta Human genes 0.000 description 1
• 108090000467 Interferon-beta Proteins 0.000 description 1
• 102000000588 Interleukin-2 Human genes 0.000 description 1
• 108010002350 Interleukin-2 Proteins 0.000 description 1
• 108090001005 Interleukin-6 Proteins 0.000 description 1
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
• 102000011782 Keratins Human genes 0.000 description 1
• 108010076876 Keratins Proteins 0.000 description 1
• 238000012218 Kunkel's method Methods 0.000 description 1
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 1
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
• 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
• 241000713666 Lentivirus Species 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• 239000012098 Lipofectamine RNAiMAX Substances 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• 101710091439 Major capsid protein 1 Proteins 0.000 description 1
• 102000013460 Malate Dehydrogenase Human genes 0.000 description 1
• 108010026217 Malate Dehydrogenase Proteins 0.000 description 1
• 208000019695 Migraine disease Diseases 0.000 description 1
• 102100023727 Mitochondrial antiviral-signaling protein Human genes 0.000 description 1
• 101710142315 Mitochondrial antiviral-signaling protein Proteins 0.000 description 1
• 201000010927 Mucositis Diseases 0.000 description 1
• 241000711408 Murine respirovirus Species 0.000 description 1
• 229930182474 N-glycoside Natural products 0.000 description 1
• 241000244206 Nematoda Species 0.000 description 1
• 229930193140 Neomycin Natural products 0.000 description 1
• 208000001132 Osteoporosis Diseases 0.000 description 1
• 239000012807 PCR reagent Substances 0.000 description 1
• 241000282577 Pan troglodytes Species 0.000 description 1
• 108010043958 Peptoids Proteins 0.000 description 1
• 102000003992 Peroxidases Human genes 0.000 description 1
• 206010035226 Plasma cell myeloma Diseases 0.000 description 1
• 239000004793 Polystyrene Substances 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• 101710089372 Programmed cell death protein 1 Proteins 0.000 description 1
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
• 101800001494 Protease 2A Proteins 0.000 description 1
• 101800001066 Protein 2A Proteins 0.000 description 1
• 101710149951 Protein Tat Proteins 0.000 description 1
• 108090000944 RNA Helicases Proteins 0.000 description 1
• 102000004409 RNA Helicases Human genes 0.000 description 1
• 239000012980 RPMI-1640 medium Substances 0.000 description 1
• 108700005075 Regulator Genes Proteins 0.000 description 1
• 108010022187 Rev peptide Proteins 0.000 description 1
• 102000006382 Ribonucleases Human genes 0.000 description 1
• 108010083644 Ribonucleases Proteins 0.000 description 1
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
• 101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• 241000700584 Simplexvirus Species 0.000 description 1
• 108020004682 Single-Stranded DNA Proteins 0.000 description 1
• 208000007107 Stomach Ulcer Diseases 0.000 description 1
• 208000004350 Strabismus Diseases 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
• 101000834248 Takifugu rubripes Actin, cytoplasmic 1 Proteins 0.000 description 1
• 108020005038 Terminator Codon Proteins 0.000 description 1
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
• 239000004473 Threonine Substances 0.000 description 1
• 108010022394 Threonine synthase Proteins 0.000 description 1
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical group O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
• 102000006601 Thymidine Kinase Human genes 0.000 description 1
• 108020004440 Thymidine kinase Proteins 0.000 description 1
• 206010044074 Torticollis Diseases 0.000 description 1
• 102000040945 Transcription factor Human genes 0.000 description 1
• 108091023040 Transcription factor Proteins 0.000 description 1
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
• 108010057266 Type A Botulinum Toxins Proteins 0.000 description 1
• 108091026822 U6 spliceosomal RNA Proteins 0.000 description 1
• 241000700618 Vaccinia virus Species 0.000 description 1
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
• 241000726445 Viroids Species 0.000 description 1
• QNEPTKZEXBPDLF-JDTILAPWSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] carbonochloridate Chemical compound C1C=C2C[C@@H](OC(Cl)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 QNEPTKZEXBPDLF-JDTILAPWSA-N 0.000 description 1
• 210000001015 abdomen Anatomy 0.000 description 1
• 239000008351 acetate buffer Substances 0.000 description 1
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
• 230000021736 acetylation Effects 0.000 description 1
• 238000006640 acetylation reaction Methods 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 229950003218 actarit Drugs 0.000 description 1
• 229960002964 adalimumab Drugs 0.000 description 1
• 239000011543 agarose gel Substances 0.000 description 1
• 206010064930 age-related macular degeneration Diseases 0.000 description 1
• 238000013019 agitation Methods 0.000 description 1
• 235000004279 alanine Nutrition 0.000 description 1
• 125000001931 aliphatic group Chemical group 0.000 description 1
• 239000002168 alkylating agent Substances 0.000 description 1
• 229940100198 alkylating agent Drugs 0.000 description 1
• 229960000711 alprostadil Drugs 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• 150000001412 amines Chemical group 0.000 description 1
• 229960000723 ampicillin Drugs 0.000 description 1
• AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 238000011861 anti-inflammatory therapy Methods 0.000 description 1
• 230000000840 anti-viral effect Effects 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 239000003435 antirheumatic agent Substances 0.000 description 1
• 239000000074 antisense oligonucleotide Substances 0.000 description 1
• 238000012230 antisense oligonucleotides Methods 0.000 description 1
• PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 125000003118 aryl group Chemical group 0.000 description 1
• 235000009582 asparagine Nutrition 0.000 description 1
• 229960001230 asparagine Drugs 0.000 description 1
• 235000003704 aspartic acid Nutrition 0.000 description 1
• RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
• 229960000396 atropine Drugs 0.000 description 1
• 150000001540 azides Chemical class 0.000 description 1
• 229940124748 beta 2 agonist Drugs 0.000 description 1
• SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
• 102000006995 beta-Glucosidase Human genes 0.000 description 1
• 108010047754 beta-Glucosidase Proteins 0.000 description 1
• DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
• 229960002537 betamethasone Drugs 0.000 description 1
• UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
• 238000002306 biochemical method Methods 0.000 description 1
• 239000012620 biological material Substances 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 208000010217 blepharitis Diseases 0.000 description 1
• 206010005159 blepharospasm Diseases 0.000 description 1
• 230000000744 blepharospasm Effects 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• 108091005948 blue fluorescent proteins Proteins 0.000 description 1
• 238000006664 bond formation reaction Methods 0.000 description 1
• 229940089093 botox Drugs 0.000 description 1
• 108010006025 bovine growth hormone Proteins 0.000 description 1
• 238000009395 breeding Methods 0.000 description 1
• 230000001488 breeding effect Effects 0.000 description 1
• 244000309464 bull Species 0.000 description 1
• 102220354910 c.4C>G Human genes 0.000 description 1
• 238000004364 calculation method Methods 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
• 230000012292 cell migration Effects 0.000 description 1
• 230000004700 cellular uptake Effects 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 235000013330 chicken meat Nutrition 0.000 description 1
• 235000019416 cholic acid Nutrition 0.000 description 1
• BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
• 229960002471 cholic acid Drugs 0.000 description 1
• 238000011210 chromatographic step Methods 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 230000002759 chromosomal effect Effects 0.000 description 1
• 210000000349 chromosome Anatomy 0.000 description 1
• 229960001265 ciclosporin Drugs 0.000 description 1
• 238000010367 cloning Methods 0.000 description 1
• 210000001072 colon Anatomy 0.000 description 1
• 238000006482 condensation reaction Methods 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 239000005289 controlled pore glass Substances 0.000 description 1
• 239000003246 corticosteroid Substances 0.000 description 1
• 229960001334 corticosteroids Drugs 0.000 description 1
• 230000008878 coupling Effects 0.000 description 1
• 238000010168 coupling process Methods 0.000 description 1
• 238000004132 cross linking Methods 0.000 description 1
• 238000005138 cryopreservation Methods 0.000 description 1
• 239000012228 culture supernatant Substances 0.000 description 1
• 238000005520 cutting process Methods 0.000 description 1
• 125000004122 cyclic group Chemical group 0.000 description 1
• 229930182912 cyclosporin Natural products 0.000 description 1
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
• 235000018417 cysteine Nutrition 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 230000007123 defense Effects 0.000 description 1
• 238000012217 deletion Methods 0.000 description 1
• 230000037430 deletion Effects 0.000 description 1
• KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
• 238000010511 deprotection reaction Methods 0.000 description 1
• 229960003957 dexamethasone Drugs 0.000 description 1
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• 238000010586 diagram Methods 0.000 description 1
• 230000004069 differentiation Effects 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
• 230000006806 disease prevention Effects 0.000 description 1
• 108010007093 dispase Proteins 0.000 description 1
• 239000012153 distilled water Substances 0.000 description 1
• 239000003651 drinking water Substances 0.000 description 1
• 235000020188 drinking water Nutrition 0.000 description 1
• 229940000406 drug candidate Drugs 0.000 description 1
• 238000012912 drug discovery process Methods 0.000 description 1
• 239000003596 drug target Substances 0.000 description 1
• 230000009977 dual effect Effects 0.000 description 1
• 230000005611 electricity Effects 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
• 230000036566 epidermal hyperplasia Effects 0.000 description 1
• 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
• 210000003560 epithelium corneal Anatomy 0.000 description 1
• 229960000403 etanercept Drugs 0.000 description 1
• 150000002170 ethers Chemical group 0.000 description 1
• 210000003527 eukaryotic cell Anatomy 0.000 description 1
• 230000005713 exacerbation Effects 0.000 description 1
• 230000003090 exacerbative effect Effects 0.000 description 1
• 102000013165 exonuclease Human genes 0.000 description 1
• 230000001815 facial effect Effects 0.000 description 1
• 238000000855 fermentation Methods 0.000 description 1
• 230000004151 fermentation Effects 0.000 description 1
• 239000012894 fetal calf serum Substances 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• ZFKJVJIDPQDDFY-UHFFFAOYSA-N fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 description 1
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
• 230000004927 fusion Effects 0.000 description 1
• 201000005917 gastric ulcer Diseases 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 238000001502 gel electrophoresis Methods 0.000 description 1
• 238000002523 gelfiltration Methods 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• 150000002334 glycols Chemical class 0.000 description 1
• 230000013595 glycosylation Effects 0.000 description 1
• 238000006206 glycosylation reaction Methods 0.000 description 1
• 230000012010 growth Effects 0.000 description 1
• 239000003102 growth factor Substances 0.000 description 1
• 229910052736 halogen Inorganic materials 0.000 description 1
• 125000005843 halogen group Chemical group 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 230000011132 hemopoiesis Effects 0.000 description 1
• 229960002897 heparin Drugs 0.000 description 1
• 229920000669 heparin Polymers 0.000 description 1
• 239000000833 heterodimer Substances 0.000 description 1
• 229920000140 heteropolymer Polymers 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 238000007489 histopathology method Methods 0.000 description 1
• 239000000710 homodimer Substances 0.000 description 1
• 229920001519 homopolymer Polymers 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 108091008039 hormone receptors Proteins 0.000 description 1
• 229920002674 hyaluronan Polymers 0.000 description 1
• 229960003160 hyaluronic acid Drugs 0.000 description 1
• 229960000890 hydrocortisone Drugs 0.000 description 1
• 239000000017 hydrogel Substances 0.000 description 1
• 230000002209 hydrophobic effect Effects 0.000 description 1
• 230000037315 hyperhidrosis Effects 0.000 description 1
• 230000003100 immobilizing effect Effects 0.000 description 1
• 230000003053 immunization Effects 0.000 description 1
• 230000007813 immunodeficiency Effects 0.000 description 1
• 230000002163 immunogen Effects 0.000 description 1
• 239000002955 immunomodulating agent Substances 0.000 description 1
• 229940121354 immunomodulator Drugs 0.000 description 1
• 230000002584 immunomodulator Effects 0.000 description 1
• 229960003444 immunosuppressant agent Drugs 0.000 description 1
• 230000001861 immunosuppressant effect Effects 0.000 description 1
• 239000000411 inducer Substances 0.000 description 1
• 230000002458 infectious effect Effects 0.000 description 1
• 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
• 208000018197 inherited torticollis Diseases 0.000 description 1
• 230000015788 innate immune response Effects 0.000 description 1
• 210000005007 innate immune system Anatomy 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 210000004347 intestinal mucosa Anatomy 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 238000005342 ion exchange Methods 0.000 description 1
• 238000004255 ion exchange chromatography Methods 0.000 description 1
• 208000001875 irritant dermatitis Diseases 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
• 229960000310 isoleucine Drugs 0.000 description 1
• GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 description 1
• 239000010410 layer Substances 0.000 description 1
• 230000029226 lipidation Effects 0.000 description 1
• 238000001638 lipofection Methods 0.000 description 1
• KNJDBYZZKAZQNG-UHFFFAOYSA-N lucigenin Chemical compound [O-][N+]([O-])=O.[O-][N+]([O-])=O.C12=CC=CC=C2[N+](C)=C(C=CC=C2)C2=C1C1=C(C=CC=C2)C2=[N+](C)C2=CC=CC=C12 KNJDBYZZKAZQNG-UHFFFAOYSA-N 0.000 description 1
• 238000004020 luminiscence type Methods 0.000 description 1
• 229940092110 macugen Drugs 0.000 description 1
• 208000002780 macular degeneration Diseases 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 210000001161 mammalian embryo Anatomy 0.000 description 1
• 238000013507 mapping Methods 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 238000000691 measurement method Methods 0.000 description 1
• KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
• 229960004963 mesalazine Drugs 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• 229930182817 methionine Natural products 0.000 description 1
• 230000000813 microbial effect Effects 0.000 description 1
• 230000002906 microbiologic effect Effects 0.000 description 1
• 239000004005 microsphere Substances 0.000 description 1
• 206010027599 migraine Diseases 0.000 description 1
• 150000002772 monosaccharides Chemical class 0.000 description 1
• 210000000214 mouth Anatomy 0.000 description 1
• 230000008066 mucocutaneous inflammation Effects 0.000 description 1
• 238000002703 mutagenesis Methods 0.000 description 1
• 231100000350 mutagenesis Toxicity 0.000 description 1
• 230000035772 mutation Effects 0.000 description 1
• 201000000050 myeloid neoplasm Diseases 0.000 description 1
• 210000003928 nasal cavity Anatomy 0.000 description 1
• 229940100662 nasal drops Drugs 0.000 description 1
• 239000013642 negative control Substances 0.000 description 1
• 229960004927 neomycin Drugs 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 229910052757 nitrogen Inorganic materials 0.000 description 1
• 210000004940 nucleus Anatomy 0.000 description 1
• 235000015097 nutrients Nutrition 0.000 description 1
• 229920001542 oligosaccharide Polymers 0.000 description 1
• 150000002482 oligosaccharides Chemical class 0.000 description 1
• 230000005868 ontogenesis Effects 0.000 description 1
• 230000002018 overexpression Effects 0.000 description 1
• FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 239000000816 peptidomimetic Substances 0.000 description 1
• 108040007629 peroxidase activity proteins Proteins 0.000 description 1
• 238000002823 phage display Methods 0.000 description 1
• 210000003800 pharynx Anatomy 0.000 description 1
• 238000005191 phase separation Methods 0.000 description 1
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
• 239000008363 phosphate buffer Substances 0.000 description 1
• 239000002953 phosphate buffered saline Substances 0.000 description 1
• 150000003904 phospholipids Chemical class 0.000 description 1
• PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
• 150000008300 phosphoramidites Chemical class 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• 230000026731 phosphorylation Effects 0.000 description 1
• 238000006366 phosphorylation reaction Methods 0.000 description 1
• 230000004962 physiological condition Effects 0.000 description 1
• 239000000419 plant extract Substances 0.000 description 1
• 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
• 229920002401 polyacrylamide Polymers 0.000 description 1
• 108010011110 polyarginine Proteins 0.000 description 1
• 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 1
• 150000004804 polysaccharides Polymers 0.000 description 1
• 229920002223 polystyrene Polymers 0.000 description 1
• 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
• 230000001124 posttranscriptional effect Effects 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 229960005205 prednisolone Drugs 0.000 description 1
• OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
• 230000035935 pregnancy Effects 0.000 description 1
• 230000003449 preventive effect Effects 0.000 description 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 210000001236 prokaryotic cell Anatomy 0.000 description 1
• 238000011321 prophylaxis Methods 0.000 description 1
• 235000019260 propionic acid Nutrition 0.000 description 1
• GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
• 125000006239 protecting group Chemical group 0.000 description 1
• 238000001243 protein synthesis Methods 0.000 description 1
• 210000001938 protoplast Anatomy 0.000 description 1
• 239000012264 purified product Substances 0.000 description 1
• IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• 239000002994 raw material Substances 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
• 230000010076 replication Effects 0.000 description 1
• 238000003571 reporter gene assay Methods 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 239000002336 ribonucleotide Substances 0.000 description 1
• 229960004889 salicylic acid Drugs 0.000 description 1
• 238000013515 script Methods 0.000 description 1
• 239000013049 sediment Substances 0.000 description 1
• 230000008684 selective degradation Effects 0.000 description 1
• 238000002864 sequence alignment Methods 0.000 description 1
• 230000008142 sex development Effects 0.000 description 1
• 238000004904 shortening Methods 0.000 description 1
• 229910052710 silicon Inorganic materials 0.000 description 1
• 239000010703 silicon Substances 0.000 description 1
• 238000001542 size-exclusion chromatography Methods 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
• 238000001179 sorption measurement Methods 0.000 description 1
• 125000006850 spacer group Chemical group 0.000 description 1
• 230000001148 spastic effect Effects 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 238000010186 staining Methods 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 239000012086 standard solution Substances 0.000 description 1
• 238000003756 stirring Methods 0.000 description 1
• 239000011550 stock solution Substances 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
• 229960001940 sulfasalazine Drugs 0.000 description 1
• 229910052717 sulfur Inorganic materials 0.000 description 1
• 239000011593 sulfur Substances 0.000 description 1
• 210000005222 synovial tissue Anatomy 0.000 description 1
• 210000002437 synoviocyte Anatomy 0.000 description 1
• 229920003002 synthetic resin Polymers 0.000 description 1
• 239000000057 synthetic resin Substances 0.000 description 1
• 239000013076 target substance Substances 0.000 description 1
• UWHCKJMYHZGTIT-UHFFFAOYSA-N tetraethylene glycol Chemical compound OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 description 1
• 229930183279 tetramycin Natural products 0.000 description 1
• 229940126585 therapeutic drug Drugs 0.000 description 1
• 230000001225 therapeutic effect Effects 0.000 description 1
• 238000002560 therapeutic procedure Methods 0.000 description 1
• 230000008719 thickening Effects 0.000 description 1
• 150000007970 thio esters Chemical class 0.000 description 1
• 230000002992 thymic effect Effects 0.000 description 1
• 229940113082 thymine Drugs 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• 231100000765 toxin Toxicity 0.000 description 1
• 108700012359 toxins Proteins 0.000 description 1
• 210000003437 trachea Anatomy 0.000 description 1
• 230000005030 transcription termination Effects 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• 241001529453 unidentified herpesvirus Species 0.000 description 1
• 241001515965 unidentified phage Species 0.000 description 1
• DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
• 210000003708 urethra Anatomy 0.000 description 1
• 229940045145 uridine Drugs 0.000 description 1
• 210000001215 vagina Anatomy 0.000 description 1
• 239000004474 valine Substances 0.000 description 1
• 210000003501 vero cell Anatomy 0.000 description 1
• 230000003612 virological effect Effects 0.000 description 1
• 239000011782 vitamin Substances 0.000 description 1
• 235000013343 vitamin Nutrition 0.000 description 1
• 229940088594 vitamin Drugs 0.000 description 1
• 229930003231 vitamin Natural products 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
• 230000029663 wound healing Effects 0.000 description 1
• 229940002639 xalatan Drugs 0.000 description 1